Ardelyx (ARDX) is back in focus after its second quarter 2026 report showed higher revenue than a year ago and a narrower net loss, along with updated full year guidance for IBSRELA and XPHOZAH.

Despite Ardelyx reporting higher year over year revenue and a narrower net loss, the stock has come under pressure, with the 30 day share price return down 24.24% and the year to date share price return down 34.96%. Even so, the 5 year total shareholder return of 166.67% contrasts with the weaker 1 year total shareholder return of 25.93%. This pattern points to momentum that has recently faded after a strong multi year run, with recent earnings guidance and the August 10 shelf registration filing likely influencing how investors weigh growth potential against funding and dilution risk.

If you are weighing Ardelyx against other potential opportunities in healthcare, this could be a good moment to scan for focused ideas in the same space via 43 healthcare AI stocks

After a drop that has pulled Ardelyx back toward the US$4 level, the decision is simple but not easy: lean into the weakness now or wait to see if dilution and execution worries are already priced in?

Most Popular Narrative: 75.5% Undervalued

At a last close of $4.00, the most followed Ardelyx narrative anchors on a fair value of $16.33 and suggests a very wide valuation gap.

The analysts have a consensus price target of $16.33 for Ardelyx based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $19.0, and the most bearish reporting a price target of just $13.0.

Want to see what is baked into that $16.33 figure? The narrative leans on rapid revenue expansion, a swing into profitability, and a richer future earnings multiple. Curious which specific assumptions carry the most weight.

The fair value estimate of $16.33 comes from discounting Ardelyx's projected cash flows at a 7.34% rate, with analysts expecting strong revenue growth, higher margins and a move into sustained profitability over time. Those projections also assume Ardelyx earns a future earnings multiple above the broader US biotech sector, supported by its IBSRELA and XPHOZAH franchises and their expected contribution to earnings power.

Result: Fair Value of $16.33 (UNDERVALUED)

However, Ardelyx still faces real pressure from its concentrated reliance on IBSRELA and XPHOZAH, as well as from reimbursement uncertainty around XPHOZAH that could unsettle the bullish narrative.

Next Steps

Does the split mood around Ardelyx leave you excited or cautious? Use the full picture of risks and rewards to firm up your stance with 4 key rewards and 1 important warning sign

Looking for more ideas beyond Ardelyx?

If Ardelyx has sharpened your interest in healthcare and growth stories, this is a great moment to broaden your watchlist with a few focused stock screens.

• Target potential mispricings by scanning 51 high quality undervalued stocks that pair solid fundamentals with compressed expectations.
• Strengthen your defensive side by reviewing 83 resilient stocks with low risk scores that score well on resilience and financial robustness.
• Get ahead of the crowd by checking the screener containing 21 high quality undiscovered gems before they attract broader attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.